Quick Dispatch:
Your surmount-1 trial tirzepatide weight loss nondiabetic SURMOUNT-1 (NEJM 2022) tested tirzepatide — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your surmount-1 trial tirzepatide weight loss nondiabetic SURMOUNT-1 (NEJM 2022) tested tirzepatide — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants ships.
Need Help?
Questions about surmount-1 trial tirzepatide weight loss nondiabetic SURMOUNT-1 (NEJM 2022) tested tirzepatide — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for surmount-1 trial tirzepatide weight loss nondiabetic SURMOUNT-1 (NEJM 2022) tested tirzepatide — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants in your area.
SURMOUNT-1 Trial
22.10
For the first time, tirzepatide and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults with obesity, no diabetes. 72 weeks. Both drugs at maximum tolerated dose. The
28.41
SURMOUNT 1 // Three-Year Obesty & Diabetes Prevention Outcomes
23.41
SURMOUNT-1: Tirzepatide Drastically Reduces Weight in Obese Patients
25.78
Tirzepatide for Obesity Treatment and Diabetes Prevention
22.64
SURMOUNT-1 Trial
20.71
SURMOUNT‐1 study design. This is a phase 3, multicenter, randomized,
29.00
